Sugi Predict

Sugi Predict / Compounds / SCHEMBL187787

SCHEMBL187787

SCHEMBL187787

O=C(O)c1ccc(O)cc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ CA12 O43570 2/20 0.57
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ CA7 P43166 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ CA14 Q9ULX7 2/20 0.57
▸ TSHR P16473 1/20 0.57
▸ ALOX5 P09917 1/20 0.52
▸ PTGS2 P35354 1/20 0.52
▸ CES2 O00748 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ ESRRG P62508 1/20 0.47
▸ ASPH Q12797 1/20 0.46
▸ POLB P06746 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HSD17B3 P37058 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11209094 0.88 CES2 (0.50) ALDH1A1CA12CA1CA2CA7
SCHEMBL4563805 0.87 CA12 (0.56) ALDH1A1CA12CA1CA2CA7
SCHEMBL24895058 0.86 CA12 (0.55) ALDH1A1CA12CA1CA2CA7
SCHEMBL323569 0.84 ESRRG (0.48) ALDH1A1CA12CA1CA2CA7
SCHEMBL31252817 0.84 ESRRG (0.48) ALDH1A1CA12CA1CA2CA7
SCHEMBL25387702 0.84 CES2 (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL29789661 0.84 CES2 (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL24177167 0.84 CES2 (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL11210255 0.82 MEN1 (0.62) ALDH1A1TSHRCES2KDM4EHPGD
SCHEMBL11207864 0.81 MAPT (0.48) ALDH1A1CES2HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114134590-B High-performance liquid crystal polyarylester fiber and preparation method and production equipment thereof 浙江甬川聚嘉新材料科技有限公司 2023-11-03 — — CN claimed
CN-116178689-A Liquid crystal polymer and preparation method and application thereof 深圳大学 2023-05-30 — — CN claimed
CN-114134590-A High-performance liquid crystal polyarylester fiber and preparation method and production equipment thereof 浙江甬川聚嘉新材料科技有限公司 2022-03-04 — — CN claimed
EP-0423991-B1 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid SHOWA SHELL SEKIYU (JP) 1995-06-14 — — EP claimed
US-5183934-A 2-trifluoromethyl-4-hydroxybenzoic acid SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) 1993-02-02 — — US claimed
EP-0423991-A2 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-24 — — EP claimed
JP-3135943-A — — None — — JP disclosed
WO-2026088205-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE INTONATION RESEARCH LABORATORIES PRIVATE LIMITED. (IN) 2026-04-30 — — WO disclosed
WO-2025202488-A1 ENHANCER OF NUCLEIC ACID AMPLIFICATION ROCHE DIAGNOSTICS GMBH (DE) 2025-10-02 — — WO disclosed
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12403198-B2 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 UPPTHERA (KR) 2025-09-02 — — US disclosed
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2025-07-10 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-5183934-A 2-trifluoromethyl-4-hydroxybenzoic acid SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) 1993-02-02 — — US disclosed
JP-H03135943-A 2-TRIFLUOROMETHYL-4-HYDROXYBENZOIC ACID SHOWA SHELL SEKIYU KK 1991-06-10 — — JP disclosed
EP-0430205-A2 Liquid cristal display device MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1991-06-05 — — EP disclosed
EP-0423991-A2 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-24 — — EP disclosed
EP-0423991-A2 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-24 — — EP disclosed
EP-0423991-A2 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-24 — — EP disclosed
EP-0409728-A2 Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1991-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, IL5, TSLP ALDH1A1 666/4885CA12 928/4885CA1 2975/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 ALDH1A1 2427/4885CA12 4394/4885CA1 4256/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALDH1A1 2427/4885CA12 4394/4885CA1 4256/4885
US-12403198-B2 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 PLK1, BUB1, BUB1B ALDH1A1 3013/4885CA12 4665/4885CA1 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.